Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a nightly eye drop stop kids' eyesight from getting worse?

NCT ID NCT07456488

Disease control Sponsor: Liaquat National Hospital & Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a very low dose of atropine eye drops (0.01%) given once nightly can slow the progression of nearsightedness (myopia) in children aged 4 to 16. Over 6 months, 60 children will either receive the drops or be in a control group. The goal is to see if the drops reduce the lengthening of the eye and slow the need for stronger glasses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atropine 0.01% eye drops
What this could lead to
If it works, this could offer a simple way to slow down worsening nearsightedness in children, reducing the need for stronger glasses later.
What could go wrong
This is a small, early-phase study with only 60 children. The effect may be modest, and long-term safety or benefits are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 4-16 years * Both genders * Myopia of baseline SER of -1.00D or more * Astigmatism less than or equal to -2.50D * No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia) * No history of other vision-threatening ocular diseases or previous intraocular surgery. * No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression. Exclusion Criteria: * Astigmatism ≥ 2.5 D * Anisometropia\>1 D * Best corrected visual acuity \< 0.5 (6/12) * Prior intraocular surgery * Allergy to atropine eye drops * Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome * History of cardiac or significant respiratory diseases * Lack of consent for participating in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focus on axial length are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focus on axial length

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • LiaquatNHMC

    RECRUITING

    Karachi, Sindh, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.